Constella (linaclotide)
- Region
- 🇪🇺 EU
- Active substance
- linaclotide
- Company
- AbbVie Deutschland GmbH & Co. KG
- Status
- Authorised
- Therapeutic area
- Irritable Bowel Syndrome
- EU approval
- Mon 26 Nov 2012
- Application
- EMEA/H/C/002490
- ATC
- A06AX04
- Official record
- www.ema.europa.eu
Indication
Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (IBS-C) in adults.
Regulatory milestones
No milestones recorded in the last year.
Follow Constella
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.